Research Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J
Importantly, the cardiovascular risk reduction was not entirely due to weight loss alone, as it occurred even in patients who failed to lose more than 5% of their body weight
To get there, we need to systematically study smaller doses of real GLP-1 therapies in people with different conditions
Similarly, if you take antihypertensive drugs or warfarin, there are theoretical interaction risks that warrant medical advice before use
Click here to book your session with Passion Health Primary Care and master your metabolism today.
Purity is independently verified by Optima Labs and certificates of analysis are available for verification at optimalabs.org